Discussion
malaria, ®
MALARIA
Whilst randomised controlled trials with epidemiological endpoints are the gold standard evidence for demonstrating the public health value of new vector control interventionsThe results from this community trial demonstrate compelling evidence of a comparable impact of VECTRON™ T500 to Fludora® Fusion in reducing the risk of malaria transmission at a community level when deployed for IRS on a large scale against a background of high coverage with pyrethroid-only ITNs. VECTRON™ T500 was non-inferior to Fludora® Fusion in reducing the human biting rate of The main reason put forward for the declining use of IRS for malaria control is the high costs and logistical constraints associated with sustaining annual IRS campaigns in high endemic settingsThe development of vector resistance to public health insecticides is recognised as a major threat to progress in achieving malaria elimination targetsGiven the goal of universal ITN coverage implemented by most national malaria control programmes, most IRS campaigns are deployed against a background of medium to high coverage with ITNs. While current WHO guidance recommends against a combined ITN and IRS approach